A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Celldex Therapeutics
ClinicalTrials.gov Identifier:
NCT01498328
First received: December 21, 2011
Last updated: July 27, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)